SLC5A2 and urinary tract infection: The meta-analysis of 68 trials showed no significant difference in urinary tract infections between SGLT2 inhibitors versus control (SGLT2 inhibitors: 2,526/29,086, control: 1,278/14,940; risk ratio (RR) 1.05, 95% confidence interval (CI) 0.98 to 1.12, I2 = 0; RD 47 more, 95% CI 19 more to 112 more per 1000 over 5 years) (Table 1 and Fig. 2).